Oncolytic virus platform racing an ~$4M cash position toward first-in-human; survival to Phase 1 dosing is the only question that matters now

Calidi is an early-stage biotech company developing an oncolytic virus therapy for non-small-cell lung cancer and head and neck cancer that is not yet approved and has not yet been tested in humans.

Calidi's RedTail platform engineers an IL-15 superagonist-expressing oncolytic virus, CLD-401, targeting NSCLC and head and neck cancer, with FDA pre-IND alignment on CMC and study design already secured. The thesis resolves entirely on whether the company can finance its way to first patient dosing, given roughly $4M cash against a $1.5M quarterly burn with no revenue. No human efficacy data exists for CLD-401, and the program has not yet entered a trial, making the biological premise entirely unproven.